Sanara MedTech Inc. (SMTI) · Oct 16, 2026 · Acquisition
FTC second request — 30-day HSR wait after substantial compliance
Sanara’s merger with MiMedx now faces an FTC second request, extending regulatory review and making the targeted year-end closing less certain.
Sanara is a pure-play surgical tissue-repair company building a broader operating-room portfolio; its planned combination with MiMedx is intended to add commercial scale across soft-tissue and musculoskeletal products. The merger has moved into a more demanding regulatory phase. Sanara and MiMedx received an FTC request for additional information and documents on October 15, 2026. 〔0〕
The immediate change is timing risk, not a failed transaction. A Second Request extends the HSR waiting period until 30 days after the parties substantially comply, unless the period is extended voluntarily or ended earlier by the FTC. That makes the previously targeted closing by the end of 2026 less certain, while leaving the merger agreement and the strategic rationale intact. The filing gives no indication that the FTC has rejected the deal; it says the companies continue to work constructively with the regulator.
This is a meaningful complication because the merger was already expected to require regulatory approval. The approval process itself was known, so the surprise is the escalation to a formal Second Request and the added information burden—not the existence of antitrust review. The deal’s proposed combination remains the route for Sanara to gain MiMedx’s scale and distribution reach, but that benefit is now further out and less certain to arrive on the original schedule.
Bottom line: The filing does not break the merger thesis, but it weakens the near-term certainty around closing by adding a substantive FTC review step. The business combination remains alive; the timetable is now the clearer point of pressure.
FTC review and substantial compliance with Second Request
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!